Cheilbio Past Earnings Performance
Past criteria checks 0/6
Cheilbio's earnings have been declining at an average annual rate of -53.4%, while the Pharmaceuticals industry saw earnings growing at 11.3% annually. Revenues have been declining at an average rate of 15.7% per year.
Key information
-53.4%
Earnings growth rate
-55.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | -15.7% |
| Return on equity | -2.6% |
| Net Margin | -6.7% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Cheilbio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 12,713 | -856 | 3,261 | 264 |
| 31 Mar 23 | 13,313 | -1,402 | 3,269 | 250 |
| 31 Dec 22 | 15,349 | -1,708 | 3,486 | 226 |
| 30 Sep 22 | 15,791 | -4,133 | 3,694 | 223 |
| 30 Jun 22 | 15,342 | -3,911 | 3,578 | 220 |
| 31 Mar 22 | 15,740 | -1,425 | 3,527 | 211 |
| 31 Dec 21 | 16,912 | -712 | 3,498 | 214 |
| 30 Sep 21 | 17,125 | 1,846 | 3,363 | 196 |
| 30 Jun 21 | 17,768 | 1,753 | 3,879 | 201 |
| 31 Mar 21 | 19,147 | 1,456 | 4,045 | 203 |
| 31 Dec 20 | 18,999 | 994 | 3,867 | 209 |
| 30 Sep 20 | 19,873 | 352 | 4,511 | 218 |
| 30 Jun 20 | 21,285 | 1,008 | 4,049 | 198 |
| 31 Mar 20 | 22,514 | 424 | 3,739 | 190 |
| 31 Dec 19 | 22,986 | 2,043 | 3,925 | 192 |
| 30 Sep 19 | 23,478 | 2,215 | 3,217 | 187 |
| 30 Jun 19 | 24,292 | 2,240 | 3,227 | 187 |
| 31 Mar 19 | 25,359 | 2,098 | 3,649 | 192 |
| 31 Dec 18 | 27,810 | 1,040 | 3,871 | 190 |
| 30 Sep 18 | 28,807 | 1,129 | 4,105 | 189 |
| 30 Jun 18 | 28,952 | 826 | 4,715 | 197 |
| 31 Mar 18 | 29,211 | 876 | 4,769 | 221 |
| 31 Dec 17 | 27,987 | 789 | 4,646 | 232 |
| 30 Sep 17 | 29,669 | 853 | 5,386 | 255 |
| 30 Jun 17 | 32,556 | 943 | 5,168 | 274 |
| 31 Mar 17 | 34,140 | 1,071 | 4,831 | 273 |
| 31 Dec 16 | 35,824 | 1,014 | 5,210 | 282 |
| 30 Sep 16 | 36,487 | 1,428 | 4,533 | 279 |
| 30 Jun 16 | 35,711 | 1,144 | 4,642 | 293 |
| 31 Mar 16 | 36,075 | 739 | 5,156 | 365 |
| 31 Dec 15 | 34,980 | 852 | 4,487 | 296 |
| 30 Sep 15 | 35,938 | 778 | 4,315 | 231 |
| 30 Jun 15 | 36,568 | 1,250 | 3,907 | 145 |
| 31 Mar 15 | 37,074 | 1,297 | 3,075 | 0 |
| 31 Dec 14 | 39,534 | 956 | 3,233 | 0 |
| 30 Sep 14 | 39,625 | 830 | 3,076 | 0 |
| 30 Jun 14 | 40,170 | 594 | 2,935 | 0 |
| 31 Mar 14 | 39,596 | 322 | 3,150 | 0 |
| 31 Dec 13 | 38,365 | 359 | 3,086 | 0 |
| 30 Sep 13 | 38,133 | 439 | 2,873 | 0 |
| 30 Jun 13 | 38,484 | 498 | 2,835 | 0 |
| 31 Mar 13 | 37,871 | 532 | 2,965 | 0 |
| 31 Dec 12 | 36,868 | 1,026 | 2,663 | 0 |
Quality Earnings: A052670 is currently unprofitable.
Growing Profit Margin: A052670 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A052670 is unprofitable, and losses have increased over the past 5 years at a rate of 53.4% per year.
Accelerating Growth: Unable to compare A052670's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A052670 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.9%).
Return on Equity
High ROE: A052670 has a negative Return on Equity (-2.64%), as it is currently unprofitable.